BIOTECH
Cilcare completes a €40M series A
December 5, 2024
The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in…
Read MoreDecember 5, 2024
The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in…
Read More